Actuate Therapeutics (ACTU) Stock Analysis: AI Score & Alternative Data
Actuate Therapeutics — alt-data steady across 90 days
Is Actuate Therapeutics a buy right now? The alternative data says hold. This ACTU stock analysis is built on the 25+ alternative data signals AltIndex tracks on Actuate Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 56/100: a Hold. The stock trades at $0.64 with a $17M market cap.
No core signal has moved more than 5% in 90 days — steady, but without the momentum that pushes a stock into buy territory.
ACTU’s broader alt-data profile also covers headcount (16 employees, according to LinkedIn), web traffic (2K monthly visits), and X followers (109). Every signal links to its own page with full history, the ACTU technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ACTU is just below.
Actuate Therapeutics AI Stock Analysis
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on the development of therapeutic agents for patients with cancer and inflammatory diseases. The company focuses on targeting the GSK-3β pathway, which is implicated in various critical cellular processes including cancer cell proliferation and inflammatory responses.
Analysis generated September 29, 2026.
Recent Actuate Therapeutics Stock Alerts
|
Actuate Therapeutics | October 9 Price is down by -6.1% in the last 24h. |
|
Actuate Therapeutics | October 8 Price is down by -6.1% in the last 24h. |
|
Actuate Therapeutics | October 7 Price is down by -23.6% in the last 24h. |
|
Actuate Therapeutics | October 6 Price is down by -7.4% in the last 24h. |
Actuate Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 2K | N/A | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 16 | N/A | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | N/A | |
| Stocktwits Mentions | 4 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 192 | N/A | |
| X Followers | 109 | N/A |
About Actuate Therapeutics (ACTU)
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative treatments for serious diseases, particularly in the oncology space. The company is advancing its proprietary drug candidates through comprehensive clinical trials, addressing significant unmet medical needs to enhance patient outcomes. With a focus on building a robust pipeline of transformative therapeutic solutions, Actuate is positioned to drive strategic growth and deliver substantial value to its investors, solidifying its competitive edge within the biotechnology industry.
| Price | $0.64 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $17M |
| Year Range | $1 – $8 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Actuate Therapeutics News
View more →| No recent news for ACTU. |
See Actuate Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for ACTU, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEActuate Therapeutics Earnings & Financial Performance
View all earnings →Actuate Therapeutics Insider Trading Activity
View all →| THOMSON TODD S filed to sell 904,795 shares at $0.0. Jan 5 '26 |
| BIOS Fund III, LP filed to sell 71,428 shares at $0.0. Jun 27 '25 |
| BIOS Fund II NT, LP filed to sell 71,428 shares at $0.0. Jun 27 '25 |
| Bios Clinical Opportunity Fund, LP filed to sell 71,428 shares at $0.0. Jun 27 '25 |
| BIOS Fund II NT, LP filed to sell 131,248 shares at $0.0. Aug 14 '24 |
Actuate Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Actuate Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Sensei BiotherapeuticsSNSE |
$13.85 6.5% | $17M | 62 |
 |
Bionano GenomicsBNGO |
$1.47 0.7% | $17M | 39 |
 |
Dyadic InternationalDYAI |
$0.47 5.3% | $18M | 53 |
 |
Dare BioscienceDARE |
$0.78 1.2% | $16M | 57 |
 |
Jasper TherapeuticsJSPR |
$0.57 1.1% | $19M | 53 |
Explore Actuate Therapeutics Data
Frequently Asked Questions: Actuate Therapeutics (ACTU)
Actuate Therapeutics has an AltIndex AI Score of 56/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
56/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Actuate Therapeutics (ACTU) stock is $0.64 with a market cap of $17M.
As of today, Actuate Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Actuate Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Actuate Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ACTU stock price chart above shows Actuate Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Actuate Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Actuate Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
